Navigation Links
Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
Date:3/29/2011

als of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec® will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; Soligenix is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec® may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec®. Factors affecting the development and use of SGX201 and LPM™ are similar to those affecting orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no oblig
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of ... Business Report" report to their offering. ... Cells (SOFCs) in US$ Thousands. The report provides separate comprehensive ... Europe , Asia-Pacific , and ... the period 2012 through 2020. Market data and analytics are ...
(Date:8/19/2014)... Md. , Aug. 19, 2014 CSSi, ... research industry, recently announced the formation of the company,s ... to announce the addition of Dr. William E. ... - http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, ... a variety of therapeutic areas and set strategic goals ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Sales Horizons, ... of its online sales skills training course ... skills. , MedTech clinical staff spend the majority of ... hospital, standalone medical center, or physician practice – providing ... But why stop there? Sales Horizons believes clinical staff ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... the most promising biotech start-up company at the recent ... a proprietary process to convert wastewater from food and ... was given top honors out of 22 total entries ... from the sponsoring Colorado law firm of Dorsey & ...
... 8 Prosolia, Inc. introduces a new,advanced Omni Spray Ion ... Omni Spray 2-D Ion Source has an automated,surface platform which ... up to 76 mm by 114 mm, which is the ... The Omni Spray 2-D Ion Source ...
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
Cached Biology Technology:Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 2Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 3Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 4Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 5Prosolia to Introduce Omni Spray(R) Ion Source in 2-D Format 2Adecco Receives Honor From Alcon Laboratories 2
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Xanex or Xanax? Or maybe Zantac? If you're a health ... , An estimated 1.3 million people in the United States ... U.S. Federal Drug Administration (FDA) has been working to reduce ... in which a patient needed an injection of Narcan but ...
... Genes & Development, Dr. Mary Ellen Perry and colleagues ... for cancer therapies. , The p53 tumor suppressor plays ... strategies aim to activate p53 in order to curb ... and therefore an attractive target to modulate p53 activity ...
... death by suicide generally decreases in the weeks after ... study led by Group Health Cooperative researchers and published ... Psychiatry. The study also found that the risk of ... less than the risk posed by older medications. ...
Cached Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
Biology Products: